Entry into a Material Definitive Agreement

Filing Overview

Registrant: Sharps Technology, Inc. The request metadata identifies Skyai, Inc., but the filing names Sharps Technology, Inc. as the registrant.

Form 8-K date: December 8, 2022; signed and filed December 13, 2022. This is a current-event filing, not a periodic financial statement.

Material Agreement

On December 8, 2022, Sharps Technology entered into a distribution agreement with Nephron Pharmaceuticals Corporation and Nephron SC, Inc. Nephron was appointed the exclusive distributor for the company’s covered products throughout the United States.

  • The initial term is two years.
  • Either party may terminate for any reason with 30 days’ notice.
  • Either party may terminate for breach with 90 days’ written notice.
  • Sharps may terminate with 60 days’ notice if specified contractual conditions are met.
  • Sharps will pay the cost of shipping products to Nephron’s warehouse.

The complete agreement was filed as Exhibit 10.1. The company also furnished a December 13, 2022 press release as Exhibit 99.1.

Financial Information

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics. It does not disclose the agreement’s pricing, minimum purchase commitments, expected sales, or projected financial impact.

Outlook, Risks, and Unusual Items

  • The agreement establishes a U.S. distribution channel but does not guarantee sales or revenue.
  • Products covered by the agreement, exclusivity terms, and commercial milestones are not detailed in the filing summary.
  • Termination rights and the absence of disclosed purchase commitments may limit the certainty of future revenue.
  • Sharps bears delivery costs to Nephron’s warehouse.
  • The company is identified as an emerging growth company.

Key Facts to Verify

  • Confirm that Sharps Technology, Inc., rather than Skyai, Inc., is the intended company.
  • Review Exhibit 10.1 for covered products, pricing, exclusivity scope, purchase obligations, milestones, and termination conditions.
  • Assess whether Nephron has committed to minimum orders or commercial launch dates.
  • Review subsequent filings for evidence of product sales, revenue recognition, manufacturing capacity, and the agreement’s actual financial impact.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.